WO2025224508 - PHARMACEUTICAL COMPOSITION FOR TREATING DEPRESSIVE DISORDERS

National phase entry is expected:
Publication Number WO/2025/224508
Publication Date 30.10.2025
International Application No. PCT/IB2025/000189
International Filing Date 21.04.2025
Title **
[English] PHARMACEUTICAL COMPOSITION FOR TREATING DEPRESSIVE DISORDERS
[French] COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DE TROUBLES DÉPRESSIFS
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
KOIKE, Yusuke
SUGIYAMA, Yuichi
Priority Data
63/637,337   22.04.2024   US
63/640,771   30.04.2024   US
63/641,890   02.05.2024   US
63/641,908   02.05.2024   US
63/691,572   06.09.2024   US
63/707,311   15.10.2024   US
63/709,014   18.10.2024   US
63/767,686   06.03.2025   US
63/767,812   06.03.2025   US
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting5165
EPO Filing, Examination, Granting85694
Japan Filing, Examination, Granting4691
South Korea Filing, Examination, Granting7273
USA Filing, Examination, Granting19940
MasterCard Visa
Total: 122,763
Contact Us
Abstract[English] Pharmaceutical compositions comprising (a) about 0.1 mg to about 5 mg 9-[4- (cyclohexyloxy)phenyl]-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2- dioxide ("COMPOUND A"); (b) a diluent; (c) a disintegrant; (d) a binder; and (e) a lubricant and methods of preparing the same are disclosed.[French] L'invention concerne des compositions pharmaceutiques comprenant (a) environ 0,1 mg à environ 5 mg de 9-[4- (cyclohexyloxy)phényl]-7-méthyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2- dioxide ("COMPOSÉ ") ; (b) un diluant ; (c) un délitant ; (d) un liant ; et (e) un lubrifiant et leurs procédés de préparation.

Rejoining the server...